[2-(1-Hydroxypropan-2-yloxy)-2-methoxyethyl] 5-[3-[[4-methyl-4-[(5-nitropyridin-2-yl)disulfanyl]pentanoyl]amino]propylamino]-5-oxopentanoate

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: [2-(1-Hydroxypropan-2-yloxy)-2-methoxyethyl] 5-[3-[[4-methyl-4-[(5-nitropyridin-2-yl)disulfanyl]pentanoyl]amino]propylamino]-5-oxopentanoate
• 英文别名: [2-(1-hydroxypropan-2-yloxy)-2-methoxyethyl] 5-[3-[[4-methyl-4-[(5-nitropyridin-2-yl)disulfanyl]pentanoyl]amino]propylamino]-5-oxopentanoate
• 化学式: C25H40N4O9S2
• 分子量: 604.7
• InChiKey: UXOMRSBFPJIYPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  40
• 可旋转键数：
  21
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  233
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：Mersana Therapeutics, Inc.

  公开号：US20160067353A1

  公开（公告）日：2016-03-10

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种药物偶联物。该偶联物包括基于蛋白质的识别分子（PBRM）和多聚载体，该多聚载体被取代了一个或多个-LD-D，基于蛋白质的识别分子通过LP与多聚载体连接。每个D的出现都是具有分子量≦5 kDa的治疗剂。LD和LP是将治疗剂和PBRM分别连接到多聚载体的连接剂。还揭示了用于与PBRM共轭形成聚合物-药物-PBRM偶联物的多聚支架，包括偶联物的组成，制备它们的方法以及使用偶联物或其组成治疗各种疾病的方法。
• [EN] PROTEIN-POLYMER-DRUG CONJUGATES<br/>[FR] CONJUGUÉS PROTÉINE-POLYMÈRE-MÉDICAMENT
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093394A1

  公开（公告）日：2014-06-19

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer- drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.